Access360
Success in China depends on understanding how policies across insurance, medicines, and medical care shape market access and commercial performance. Access360 is our real-time policy intelligence platform that tracks and interprets evolving developments in pricing, coverage, reimbursement, and care delivery—translating them into market-grounded, cross-portfolio insights to guide strategic decisions, including:
- Early insight into China access shifts impacting global pricing, margins, and launch sequencing — supporting risk-adjusted trade-offs
- Visibility into revenue risks, growth drivers, and execution challenges within China’s policy environment
- Alignment of China policy trends with launch playbooks, GTM models, and brand strategy
- Portfolio-level visibility and policy context to prioritize markets, guide resource allocation, and support investment timing
With Access360, your leadership team will:
- Receive timely, expert policy interpretations that distill complex reforms into clear and actionable implications
- Participate in our annual live Executive Debrief, where we distill the year’s pivotal policy developments and unpack their commercial consequences
Exclusive 2025–2026 Access
During 2025 and 2026, teams also have access to the C-List Masterclass archive, offering timely insights to capture opportunities and manage risks as China transitions toward a multi-level coverage framework.
Access360 is available through team subscriptions. To learn more, contact us today.
